{
    "nctId": "NCT02696759",
    "briefTitle": "Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer",
    "officialTitle": "The Gut Microbiome and Gastrointestinal Toxicities as Determinants of the Response to Neoadjuvant Chemotherapies for Advanced Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Number of Subjects Who Complete Fecal Collection",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with invasive breast cancer and prescribed a regimen that includes neo-adjuvant therapy prior to breast surgery.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* History of previous malignancy, other than non-melanoma skin cancers\n* Inability to tolerate phlebotomy\n* Immunosuppressive therapy for any other condition\n* Fever or active uncontrolled infection in the last 4 weeks\n* Inflammatory bowel disease\n* Surgery of the stomach, small or large intestines, appendectomy, gastric bypass or gastric banding in the past 6 months.\n* Active autoimmune disease, including, but not limited to, Systemic lupus erythematosus (SLE), Multiple sclerosis (MS), ankylosing spondylitis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}